Jan 07, 2020
genOway and Merck Strengthen CRISPR/Cas9 Strategic Alliance by Extending Their Partnership to All Animal Cell Models
Dec 10, 2019
Caris Life Sciences to Present Data Evaluating PI3K Pathway Alterations at the 2019 San Antonio Breast Cancer Symposium (SABCS)
Nov 27, 2019
Protalix BioTherapeutics Hosting Key Opinion Leader Meeting on PRX-102 Drug Candidate for the Treatment of Fabry Disease
Nov 18, 2019
Protalix BioTherapeutics and Chiesi Farmaceutici Announce Successful pre-BLA Meeting with FDA for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States
Nov 07, 2019
Protalix BioTherapeutics Reports Third Quarter 2019 Results and Provides Corporate Update
Nov 06, 2019
Trovagene Announces Data from Acute Myeloid Leukemia (AML) Phase 1b/2 Trial of Onvansertib Chosen for Oral Presentation at ASH 2019 Annual Meeting
Nov 05, 2019
Ryvu Therapeutics to Present at BIO-Europe 2019
Oct 29, 2019
Tolero Pharmaceuticals Presents Findings from Preclinical Studies Evaluating Investigational Agents TP-1287 in Prostate Cancer Models and TP-1454 in Colorectal Cancer Models
Oct 25, 2019
European Commission Approves Astellas' XOSPATA(TM) (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
Oct 08, 2019
Health Canada approves CALQUENCE® (acalabrutinib) for adult patients with previously-treated mantle cell lymphoma (MCL)
Sep 24, 2019
Protalix BioTherapeutics and Chiesi Group Complete Enrollment in the Third Phase III Clinical Trial of pegunigalsidase alfa (PRX-102) for the Treatment of Fabry Disease
Sep 23, 2019
ESMO Annual Meeting 2019: Menarini Ricerche Presents the Preclinical Characterization of MEN1611, a Novel PI3K Inhibitor in Development for the Treatment of Breast Cancer
Sep 19, 2019
Trovagene Announces Successful Completion of Phase 1b Trial of Onvansertib in Acute Myeloid Leukemia (AML) and Initiation of Patient Enrollment in Phase 2
Sep 12, 2019
Global and Chinese Market Aldolase Market Insights, 2014-2019 & 2019-2024 by Manufacturers, Product Type, Application, and Technology - ResearchAndMarkets.com
Sep 06, 2019
Selvita Announces First Patient Dosed in Phase 1b Study of CDK8 Inhibitor SEL120 in the Treatment of Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Sep 03, 2019
Selvita to Present at Upcoming Conferences in September
Aug 13, 2019
Researchers Study Ancestors of Proteins to Understand Their Role in Growth
Aug 05, 2019
3-V Biosciences Changes Name to Sagimet Biosciences and Closes $25 Million Financing
Jul 23, 2019
The adoption of PDE inhibitors and drive the market at a CAGR of almost 6% during the forecast period
Jul 23, 2019
University of California granted two new U.S. CRISPR-Cas9 patents